cents and 16- to 26-year-old Adult Women ---------------------------------------------------------------------- 9- to 15-year-old 16- to 26-year-old Female Adolescents Adult Women (Protocols 016 and 018) (Protocols 013 and 015) Assay N = 1121 N = 4229 (cLIA) -------------------------------------------------------- n GMT (95% CI) n GMT (95% CI) ====================================================================== Anti-HPV 6 915 928.7 (874.0, 986.8) 2631 542.6 (526.2, 559.6) ---------------------------------------------------------------------- Anti-HPV 11 915 1303.0 (1223.1, 1388.0) 2655 761.5 (735.3, 788.6) ---------------------------------------------------------------------- Anti-HPV 16 913 4909.2 (4547.6, 5299.5) 2570 2293.9 (2185.0, 2408.2) ---------------------------------------------------------------------- Anti-HPV 18 920 1039.8 (964.9, 1120.4) 2796 461.6 (444.0, 480.0) ---------------------------------------------------------------------- Note: GMT = Geometric mean titer in mMU/mL (mMU = milli-Merck units). ---------------------------------------------------------------------- Anti-HPV responses 1 month Postdose 3 among 9- to 15-year-old girls were non-inferior to anti-HPV responses in 16- to 26-year-old adolescent and young adult women in the combined database of immunogenicity studies for GARDASIL. On the basis of this immunogenicity bridging, the efficacy of GARDASIL in 9- to 15-year-old girls is inferred. Studies with Other Vaccines The safety and immunogenicity of co-administration of GARDASIL with hepatitis B vaccine (recombinant) (same visit, injections at separate sites) were evaluated in a randomized study of 1871 women aged 16 to 24 years at enrollment. Immune response to both hepatitis B vaccine (recombinan
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
Related medicine technology :

1. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
2. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
7. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
8. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
9. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
10. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics